{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-038309","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.266167+00:00","generated_at":"2026-06-17T11:15:28.140997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Journey Medical reports record FY22 revenue of $73.7M (+17% YoY); net loss narrows to $29.6M","bullets":["Record total revenues of $73.7M for FY2022, up 17% from $63.1M in FY2021.","Net loss of $29.6M ($1.69/share) vs $44.0M ($4.32/share) in prior year; Adjusted EBITDA -$7.3M.","Phase 3 DFD-29 (rosacea) fully enrolled; topline data expected H1 2023; NDA filing H2 2023.","Q4 2022 revenue $16.0M, down 9% YoY due to Targadox generic competition.","SG&A expenses rose to $59.5M from $39.8M; R&D decreased to $10.9M from $16.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-038309","json":"https://secwatch.observer/filing/0001104659-23-038309.json","markdown":"https://secwatch.observer/filing/0001104659-23-038309.md","text":"https://secwatch.observer/filing/0001104659-23-038309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/tm236285d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:15:28.140997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0deab07617fbd19e5145a754c15035a7d30e308b","claim":"Journey Medical Corp reported fourth quarter and full year ended December 31, 2022 results: revenue Total revenues were $73.7 million for the full year 2022, net income Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022, EPS $1.69 per share basic and diluted.","evidence_excerpt":"Total revenues were $73.7 million for the full year 2022, a record high for the Company, compared to total revenues of $63.1 million for the full year 2021, representing 17% growth.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"Total revenues were $73.7 million for the full year 2022"},{"label":"Net income","value":"Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022"},{"label":"EPS","value":"$1.69 per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8a8f8ed6e6b70a29f2f303e492ebf3b4d3b1012f","claim":"Journey Medical Corp reported fourth quarter ended December 31, 2022 results: revenue total revenues of $16.0 million for the fourth quarter of 2022, net income Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022, EPS $0.60 per share basic and diluted.","evidence_excerpt":"This includes total revenues of $16.0 million for the fourth quarter of 2022, compared to net revenues of $17.5 million generated in the fourth quarter of 2021, representing a 9% decline from period-to-period primarily due to generic competition for Targadox.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"total revenues of $16.0 million for the fourth quarter of 2022"},{"label":"Net income","value":"Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022"},{"label":"EPS","value":"$0.60 per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}